• Reserpine was compared with a placebo in 145 studies involving 180 ambulatory patients who underwent treatment for chronic alcoholism. The final comparison involved 33 patients who received the placebo and 112 patients who received either 0.25 or 0.5 mg. of reserpine by mouth twice a day. Whether a given patient was receiving reserpine or the placebo was known to the druggist and secretary, but not to the patient or his physician. At the conclusion of the period of study, of the 112 patients who received reserpine, 80 (71%) were reported as slightly improved, moderately improved, or well; of the 33 (21%) who received the placebo, only 7 were so reported. Improvement was considered significant in more than half of the patients who received reserpine.
Wells RE. USE OF RESERPINE (SERPASIL) IN THE MANAGEMENT OF CHRONIC ALCOHOLISM. JAMA. 1957;163(6):426–429. doi:10.1001/jama.1957.02970410016006
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: